arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

20/20 Biolabs, Inc.

AIDX

$0.44 ▼ -0.01 (-2.84%) at close

5 Visible periods

24 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

20/20 Biolabs, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.4M

Dividend Yield —

Revenue Growth -36.2%

Op. Margin -408.4%

ROIC -44.7%

FCF / Share $-0.17

Trailing P/E —

Price / Book 1.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 5, 2026.

5-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$353.38K

↓ -36.2% —

Net Income Profit after all expenses

$-2.17M

↓ -184.4% —

Operating Margin Operating profit as % of sales

-408.4%

↓ -192.9% 1th

FCF / Share Free cash flow per share

$-0.17

↓ -66.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Revenue Growth YoY (%)	-36.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-824%)	—	—	—	—
EPS Growth YoY (%)	-75.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-184.4% Weak Weak Year-over-year change in net income	—	—	—	—
FCF Growth YoY (%)	-66.3% Weak Weak Year-over-year change in free cash flow	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Operating Margin (%) (%)	-408.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3504%)	—	-139.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1262%)	—	—
Profit Margin (%) (%)	—	—	-138.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1826%)	—	—
FCF Margin (%) (%)	-364.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-88.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.59x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Return on Invested Capital (%)	-44.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	-57.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-24.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-85.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-668%)	—	-71.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-580%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Net Debt (USD)	$-4.22M	$-1.03M	—	$-1.78M	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Revenue per Share (USD)	$0.05	—	$0.11	—	—
Basic EPS, GAAP (USD)	$-0.28	—	$-0.16	—	—
Free Cash Flow per Share (USD)	$-0.17	—	$-0.10	—	—
Book Value per Share (USD)	$0.24	$-0.00	$0.22	$0.31	—
Tangible Book Value per Share (USD)	$0.22	$-0.04	$0.22	$0.27	—
Basic Weighted Avg Shares (shares)	7.66M	—	4.82M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Working Capital (USD)	$2.12M	$-992.01K	—	$679.15K	—
Total Equity (USD)	$2.55M	$-19.23K	$1.06M	$1.51M	$4.29M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗
Sales/Revenue/Turnover (USD)	$353.38K	—	$553.82K	—	—
Depreciation Expense (USD)	$12.31K	—	$17.82K	—	—
Net Income, GAAP (USD)	$-2.17M	—	$-764.58K	—	—
Operating Cash Flow (USD)	$-1.29M	—	$-488.29K	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 5 quarters

20/20 Biolabs, Inc.

Analytical Summary

5-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare AIDX with peers